Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 12/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25013972 | 0.85 | GBA1 (0.57) | GBA1HRH4HRH3HSP90AB1 | |
| SCHEMBL18757234 | 0.81 | GBA1 (0.41) | GBA1HRH4HRH3 | |
| SCHEMBL19464603 | 0.80 | GBA1 (0.40) | GBA1HRH4HRH3 | |
| SCHEMBL22645967 | 0.79 | GBA1 (0.51) | GBA1HRH4HRH3HSP90AB1 | |
| SCHEMBL21097021 | 0.78 | GBA1 (0.50) | GBA1HRH4HRH3 | |
| SCHEMBL26699510 | 0.76 | DRD2 (0.37) | GBA1HRH4HRH3 | |
| SCHEMBL19406194 | 0.75 | GBA1 (0.48) | GBA1HRH4HRH3HSP90AB1 | |
| SCHEMBL23974875 | 0.75 | GBA1 (0.47) | GBA1HRH4HRH3 | |
| SCHEMBL18757224 | 0.74 | GBA1 (0.47) | GBA1HRH4HRH3 | |
| SCHEMBL19224835 | 0.73 | GBA1 (0.46) | GBA1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | GBA1 4194/4885HRH4 2/4885HRH3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.